cloridrato de dexmedetomidina
aché laboratórios farmacêuticos s.a - hipnoticos
cymbi
ems sigma pharma ltda - cloridrato de duloxetina - antidepressivos
cloridrato de duloxetina
legrand pharma indÚstria farmacÊutica ltda - cloridrato de duloxetina - antidepressivos
sozz
biolab farma genericos ltda - cloridrato de duloxetina - antidepressivos
cloridrato duloxetina
nova quimica farmacÊutica s/a - cloridrato de duloxetina - antidepressivos
cloridrato de duloxetina
germed farmaceutica ltda - cloridrato de duloxetina - antidepressivos
mydulo
germed farmaceutica ltda - cloridrato de duloxetina - antidepressivos
cloridrato de dexmedetomidina
sanval comÉrcio e indÚstria ltda - cloridrato de dexmedetomidina - hipnoticos
calquence
astrazeneca ab - acalabrutinib - leucemia, linfocítica, crônica, células b - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.
dasatinib accord
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - agentes antineoplásicos - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.